Search results for "ZOL"

showing 10 items of 4792 documents

AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats.

2008

Several enzymatic sources of reactive oxygen species (ROS) were described as potential reasons of eNOS uncoupling in diabetes mellitus. In the present study, we investigated the effects of AT1-receptor blockade with chronic telmisartan (25 mg/kg/day, 6.5 weeks) therapy on expression of the BH4-synthesizing enzyme GTP-cyclohydrolase I (GCH-I), eNOS uncoupling, and endothelial dysfunction in streptozotocin (STZ, 60 mg/kg iv, 7 weeks)-induced diabetes mellitus (type I). Telmisartan therapy did not modify blood glucose and body weight. Aortas from diabetic animals had vascular dysfunction as revealed by isometric tension studies (acetylcholine and nitroglycerin potency). Vascular and cardiac RO…

Blood GlucoseMalemedicine.medical_specialtyNitric Oxide Synthase Type IIImedicine.disease_causeBiochemistryBenzoatesReceptor Angiotensin Type 1chemistry.chemical_compoundEnosPhysiology (medical)Internal medicinemedicineDiabetes MellitusAnimalsTelmisartanEndothelial dysfunctionRats WistarXanthine oxidaseGTP CyclohydrolaseNADPH oxidasebiologySuperoxideBody WeightNADPH Oxidasesmedicine.diseaseStreptozotocinbiology.organism_classificationMitochondriaRatsUp-RegulationEnzyme ActivationOxidative StressEndocrinologychemistrybiology.proteinBenzimidazolesTelmisartanAngiotensin II Type 1 Receptor BlockersOxidative stressmedicine.drugFree radical biologymedicine
researchProduct

Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking.

1997

Cigarette smoking within minutes induces leukocyte adhesion to the vascular wall and formation of intravascular leukocyte-platelet aggregates. We find this is inhibited by platelet-activating factor (PAF) receptor antagonists, and correlates with the accumulation of PAF-like mediators in the blood of cigarette smoke-exposed hamsters. These mediators were PAF-like lipids, formed by nonenzymatic oxidative modification of existing phospholipids, that were distinct from biosynthetic PAF. These PAF-like lipids induced isolated human monocytes and platelets to aggregate, which greatly increased their secretion of IL-8 and macrophage inflammatory protein-1alpha. Both events were blocked by a PAF r…

Blood PlateletsChemokineAntioxidantTime FactorsPlatelet Aggregationmedicine.drug_classNeutrophilsmedicine.medical_treatmentPhospholipidReceptors Cell SurfaceAscorbic AcidPlatelet Membrane GlycoproteinsPharmacologyAntioxidantsMonocytesReceptors G-Protein-Coupledchemistry.chemical_compoundReference ValuesCricetinaemedicineCell AdhesionAnimalsHumansPlateletPlatelet Activating FactorReceptorChemokine CCL4Cell AggregationLeukocyte aggregationbiologyPlatelet-activating factorChemistryInterleukin-8SmokingGeneral MedicineAzepinesMacrophage Inflammatory ProteinsTriazolesReceptor antagonistBiochemistrybiology.proteinlipids (amino acids peptides and proteins)Platelet Aggregation InhibitorsResearch Article
researchProduct

Eltrombopag in chronic hepatitis C

2014

Chronic hepatitis C is a public health problem worldwide. Unfortunately, not all patients may benefit from antiviral therapy due to thrombocytopenia. Its causes are represented by portal hypertension and platelet sequestration in the spleen, decreased serum levels or activity of thrombopoietin, the bone marrow suppression induced by hepatitis C virus and a possible adverse effect of interferon. Thrombopoietin receptor analogs may contribute to increase platelet counts in these patients. Eltrombopag binds to another region of the thrombopoietin receptor compared to endogenous thrombopoietin and stimulates the proliferation and maturation of megakaryocytes and the platelet production in a dos…

Blood PlateletsCirrhosisHepatitis C virusEltrombopagmedicine.disease_causeAntiviral AgentsBenzoatesThrombopoiesischemistry.chemical_compoundRisk FactorsHematologic AgentsmedicineHumansThrombopoiesisThrombopoietinThrombopoietin receptorbusiness.industryGastroenterologyBone marrow failureMinireviewsGeneral MedicineHepatitis C Chronicmedicine.diseaseThrombocytopeniaHydrazinesTreatment OutcomeBone marrow suppressionchemistryImmunologyPyrazolesbusinessReceptors ThrombopoietinSignal TransductionWorld Journal of Gastroenterology
researchProduct

Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity.

2001

One of the best known bioactive triterpenoids is oleanolic acid, a widespread 3-hydroxy-17-carboxy oleanane-type compound. In order to determine whether further oxidation of carbon 3 affects anti-inflammatory activity in mice, different tests were carried out on oleanolic acid and its 3-oxo-analogue oleanonic acid, which was obtained from Pistacia terebinthus galls. The last one showed activity on the ear oedema induced by 12-deoxyphorbol-13-phenylacetate (DPP), the dermatitis induced by multiple applications of 12-O-tetradecanoyl-13-acetate (TPA) and the paw oedemas induced by bradykinin and phospholipase A2. The production of leukotriene B4 from rat peritoneal leukocytes was reduced by ol…

Blood PlateletsLeukotrienesLeukotriene B4medicine.drug_classNeutrophilsBradykininTetrazolium SaltsIn Vitro TechniquesLeukotriene B4Anti-inflammatorychemistry.chemical_compoundMiceStructure-Activity RelationshipPhospholipase A2medicineAnimalsEdemaHumansCyclooxygenase InhibitorsHypersensitivity DelayedEar ExternalOleanolic AcidOleanolic acidPeroxidasePharmacologyInflammationLeukotrienebiologyFootAnti-Inflammatory Agents Non-SteroidalBiological activityTriterpenesRatsThiazoleschemistryBiochemistryArachidonate 5-lipoxygenasePistaciabiology.proteinFemaleDrug Screening Assays AntitumorOxidation-ReductionEuropean journal of pharmacology
researchProduct

PHOSPHODIESTERASE INHIBITORS PIROXIMONE AND ENOXIMONE INHIBIT PLATELET AGGREGATION IN VIVO AND IN VITRO

1997

The phosphodiesterase type III inhibitors piroximone (PIR) and enoximone (ENO) exert positive inotropic and vasodilating effects in patients with severe heart failure. PIR and ENO raise cyclic AMP levels in cardiac and vascular smooth muscle cells. Platelet activity is also regulated by intracellular levels of cyclic AMP. In this study we have investigated the effects of PIR and ENO on platelet activity in vivo and in vitro. PIR and ENO inhibited ADP induced platelet aggregation in a time- and concentration-dependent manner with IC50-values of 67 +/- 14 mumol/l and 129 +/- 6 mumol/l, respectively. Coincubation of PIR with the adenylate cyclase activator iloprost resulted in a synergistic po…

Blood PlateletsMalemedicine.medical_specialtyCardiotonic AgentsVascular smooth musclePlatelet AggregationPhosphodiesterase InhibitorsVasodilationIn vivoInternal medicineCyclic AMPmedicineAnimalsHumansEnoximonePlateletPlatelet activationRats WistarEnoximonebiologyChemistryImidazolesPhosphodiesteraseHematologyRatsEndocrinologyEnzyme inhibitorbiology.proteinCalciumPlatelet Aggregation Inhibitorsmedicine.drugThrombosis Research
researchProduct

Spectrofluorimetric Quantification of Malondialdehyde for Evaluation of Cyclooxygenase-1/Thromboxane Synthase Inhibition

1999

The in vitro assay developed by Hartmann and Ledergerber (1995) utilizing the spectrofluorimetric quantification of malondialdehyde after reaction with thiobarbituric acid was modified and used for further investigations. The human whole blood was replaced by a platelet suspension of pig blood, and calcium ionophore A23187 was used instead of collagen for inducing the arachidonic acid cascade. The modified assay represents a simple, time and cost saving method for the evaluation of cyclooxygenase-1/thromboxane synthase inhibition. The reproducibility and comparability of results is given. Additional experiments allow classification of selective phospholipase A2, cyclooxygenase-1, and thromb…

Blood PlateletsSwineThiobarbituric acidPharmaceutical ScienceCyclooxygenase pathwaychemistry.chemical_compoundPhospholipase A2MalondialdehydeDrug DiscoveryAnimalsHumansCyclooxygenase InhibitorsDrug InteractionsPlateletEnzyme InhibitorsDose-Response Relationship DrugbiologyImidazolesMembrane ProteinsReproducibility of ResultsThiobarbituratesMalondialdehydeIsoenzymesSpectrometry FluorescencechemistryBiochemistryProstaglandin-Endoperoxide SynthasesCyclooxygenase 1biology.proteinArachidonic acidThromboxane-A SynthaseThromboxane-A synthaseCyclooxygenaseArchiv der Pharmazie
researchProduct

Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice

2010

Abstract Background P-glycoprotein (P-gp), an efflux transporter localized in the blood–brain barrier, limits the access of multiple xenobiotics to the central nervous system (CNS). For the new antipsychotic aripiprazole and its active metabolite dehydroaripiprazole differences in disposition in blood and brain were investigated after acute and sub-chronic administration in a P-gp knockout mouse model. Methods Serum and brain concentrations of both drugs were measured at several time points 1–24 h after i.p. injection of 10 mg/kg aripiprazole and after 11 days of sub-chronic administration in several tissues. Moreover, the expression of P-gp was determined by Western blot analysis after sub…

Blotting WesternCentral nervous systemAripiprazoleQuinolonesPharmacologyBlood–brain barrierMass SpectrometryPiperazinesMiceCellular and Molecular NeurosciencePharmacokineticsmedicineAnimalsATP Binding Cassette Transporter Subfamily B Member 1Chromatography High Pressure LiquidActive metaboliteP-glycoproteinMice KnockoutPharmacologyAnalysis of VariancebiologyChemistryBrainBiological TransportTransportermedicine.anatomical_structureBlood-Brain BarrierKnockout mousebiology.proteinAripiprazoleAntipsychotic Agentsmedicine.drugNeuropharmacology
researchProduct

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evalu…

2022

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawZoledronic acid; Denosumab; Bone metastases; Solid cancer; Osteonecrosis of the jaw; MRONJCost-Benefit AnalysisBone metastasesSolid cancerPamidronateBone NeoplasmsMRONJRisk AssessmentOncologyQuality of LifeHumansBisphosphonate-Associated Osteonecrosis of the JawDenosumabZoledronic acid
researchProduct

Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review

2015

Introduction: Orthodontic anchorage is one of the most challenging aspects of Orthodontics. Preventing undesired movement of teeth could result in safer and less complicated orthodontic treatment. Recently, several reviews have been published about the effects of different molecules on bone physiology and the clinical side effects in Orthodontics. However, the effects of local application of these substances on the rate of orthodontic tooth movement have not been assessed.Objectives: The aim of this research was to analyze the scientific evidence published in the literature about the effects of different molecules on orthodontic anchorage.Methods: The literature was systematically reviewed …

Bone remodeling periodBisfosfonatosTooth Movement TechniquesMovimentação dentáriaPharmacological managementAnti-Inflammatory AgentsOsteoclastsPamidronateDentistryZoledronic AcidAntioxidantsLactonesMiceStilbenesOrthodontic Anchorage ProceduresMedicineAgentes anti-inflamatóriosSulfonesAnti-inflammatory agentsOrthodonticsDiphosphonatesOsteoprotegerinaImidazolesOrthodontic anchorage proceduresArticlesBisphosphonatesProcedimentos de ancoragem ortodônticaTooth movementInclusion and exclusion criteriaBone RemodelingTooth MobilityOral SurgeryDiclofenacMEDLINEOrthodonticsKappa indexInterferon-gammaAnimalsHumansbusiness.industryOsteoprotegerinBone physiologyIsoxazolesOrthodontic Anchorage ProceduresAcetylcysteineRatslcsh:RK1-715CelecoxibResveratrolTooth movementlcsh:DentistryClodronic Acidbusiness
researchProduct

Synthesis and Photodynamics of Fluorescent Blue BODIPY-Porphyrin Tweezers Linked by Triazole Rings

2012

Novel zinc porphyrin tweezers in which two zinc porphyrins were connected with π-conjugated boron dipyrromethenes (BDP meso-Por(2) and BDP β-Por(2)) through triazole rings were synthesized to investigate the photoinduced energy transfer and electron transfer. The UV-vis spectrum of BDP β-Por(2) which has less bulky substituents than BDP meso-Por(2) exhibits splitting of the Soret band as a result of the interaction between porphyrins of BDP β-Por(2) in the excited state. Such interaction between porphyrins of both BDP β-Por(2) and BDP meso-Por(2) is dominant at room temperature, while the coordination of the nitrogen atoms of the triazole rings to the zinc ions of the porphyrins occurs at l…

Boron CompoundsOptical TweezersMetalloporphyrinsPhotochemistrySpectrum AnalysisTriazolechemistry.chemical_elementZincTriazolesPhotochemistryPorphyrinFluorescenceZincchemistry.chemical_compoundElectron transferEnergy TransferchemistryExcited stateFlash photolysisPhysical and Theoretical ChemistryBODIPYThe Journal of Physical Chemistry A
researchProduct